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ARTICLE
Breast and pancreatic cancer interrupt
IRF8-dependent dendritic cell development to
overcome immune surveillance
Melissa A. Meyer1, John M. Baer1, Brett L. Knolhoff1, Timothy M. Nywening2, Roheena Z. Panni1,2, Xinming Su1,
Katherine N. Weilbaecher1,3, William G. Hawkins2,3, Cynthia Ma1,3, Ryan C. Fields2,3, David C. Linehan4,
Grant A. Challen1,3,5, Roberta Faccio6, Rebecca L. Aft2,3,7 & David G. DeNardo1,3,8
Tumors employ multiple mechanisms to evade immune surveillance. One mechanism is
tumor-induced myelopoiesis, whereby the expansion of immunosuppressive myeloid cells
can impair tumor immunity. As myeloid cells and conventional dendritic cells (cDCs) are
derived from the same progenitors, we postulated that myelopoiesis might impact cDC
development. The cDC subset, cDC1, which includes human CD141+ DCs and mouse
CD103+ DCs, supports anti-tumor immunity by stimulating CD8+ T-cell responses. Here, to
understand how cDC1 development changes during tumor progression, we investigated cDC
bone marrow progenitors. We found localized breast and pancreatic cancers induce systemic
decreases in cDC1s and their progenitors. Mechanistically, tumor-produced granulocyte-
stimulating factor downregulates interferon regulatory factor-8 in cDC progenitors, and thus
results in reduced cDC1 development. Tumor-induced reductions in cDC1 development
impair anti-tumor CD8+ T-cell responses and correlate with poor patient outcomes. These
data suggest immune surveillance can be impaired by tumor-induced alterations in cDC
development.
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To subvert immune surveillance, solid tumors disrupttumor-targeted immune responses. Conventional dendriticcells (cDCs) support anti-tumor adaptive immunity by
stimulating T cells, but cDCs often fail to accumulate in the
tumor microenvironment1,2. Furthermore, those cDCs found in
the tumor can be immature and are therefore less effective in
antigen presentation and T-cell stimulation3–6. Solid tumors also
interfere with anti-tumor immune responses by stimulating
immature granulocyte and monocyte production from bone
marrow (BM) progenitors. Expanded myeloid cells are recruited
to tumors where they can maintain an immature phenotype or
differentiate into tumor-associated macrophages. All of these
populations can suppress anti-tumor CD8+ T cells as well as
promote tumor progression through support of angiogenesis and
metastasis7–10. Interestingly, cDCs are produced from the same
BM progenitors as the expanding populations of granulocytes and
monocytes11,12. Although granulocyte and monocyte differ-
entiation is known to be dysregulated in cancer7–10, we do not
fully understand how tumors affect cDC differentiation. Because
of their common origin, we hypothesized that tumor-induced
expansion of immature granulocytes and monocytes occur at the
expense of cDC differentiation.
cDCs play an important role in initiating and maintaining
adaptive immune responses. cDCs are split into two subsets:
cDC1s, which specialize in CD8+ T-cell activation, and cDC2s,
which specialize in CD4+ T-cell activation. The cDC1s are
marked by CD141 in humans and encompass both migratory
CD103+ cDC1s and lymphoid-resident CD8α+ cDC1s in mice.
cDC2s are also found in both lymphoid and peripheral tissues
and are marked by CD1c in humans and CD11b and Sirpα in
mice13–16. The development of cDC1s is driven by the tran-
scription factors interferon regulatory factor-8 (IRF8), basic leu-
cine zipper transcription factor ATF-like 3 (Batf3), and inhibitor
of DNA binding 2 (Id2)13,17–19. The development of cDC2s is
driven by a different set of transcription factors including inter-
feron regulatory factor 4 (IRF4).
Because of their role in activating CD8+ T cells, cDC1s have
been implicated in supporting the T-cell response against solid
tumors. CD103+ cDC1s are known to cross-present antigen to
activate CD8+ T cells and secrete factors that attract T cells into
the tumor18,20,21. Furthermore, CD103+ cDC1s are important for
transporting antigen into the draining lymph nodes (LNs), sup-
porting T-cell activation and expansion2,22,23. Given these func-
tions, it is understandable that CD103+ cDC1s have been
implicated in initiation and maintenance of CD8+ T-cell
responses against tumors. CD103+ cDC1s are required to
restrain tumor growth and support response to CD8+ T cell-
mediated chemo- and immune-therapies in multiple mouse
models of solid tumors. In patients, intratumoral CD141+ cDC1
numbers correlate with better outcomes in many types of solid
tumors, including breast cancer (BC)1–3,18,24–26. Thus, cDC1s are
important mediators of the anti-tumor CD8+ T-cell response and
can function to control tumor progression in mice and humans.
Given their important role in supporting anti-tumor immunity,
we inquired whether tumor progression affects the generation of
cDCs. Recent work has shown that after committing to the
granulocyte, monocyte, or cDC lineage, cDC precursors can
commit to the cDC1 subset during differentiation before leaving
the BM27–31. Given that differentiation choice can be made
outside the tumor microenvironment, we hypothesized that sys-
temic changes induced by tumors might impair cDC, and further
cDC1, commitment in the BM, and subsequently inﬂuence
cDC1s in the periphery and anti-tumor immunity. In this study,
we show that tumors interrupt cDC, and speciﬁcally cDC1, dif-
ferentiation in BC and pancreatic ductal adenocarcinoma
(PDAC) mouse models and patients. This interruption reduces
the systemic cDC1 pool, negatively impacting CD8+ T-cell
immunity and correlating with poor patient outcome. Our data
illustrate a new mechanism by which tumors subvert anti-tumor
immunity via dysregulation of cDC1 differentiation.
Results
BC and PDAC patients have reduced BM cDC differentiation.
cDCs are important for initiating and sustaining anti-tumor T-
cell responses1,2,22. To understand the impact of tumors on
development of cDCs, we proﬁled BM samples from human BC
and PDAC patients with localized disease and no prior therapy.
We analyzed the following cDC progenitors: macrophage-
dendritic cell progenitors (MDPs), which retain monocyte/mac-
rophage potential; common dendritic cell progenitors (CDPs),
which retain plasmacytoid DC (pDC) potential; and pre-DCs,
which are committed to the cDC lineage. Relative to BM from
healthy controls, BM from both BC and PDAC patients had
decreased numbers of CDPs and pre-DCs. MDPs were reduced in
BC patients but not PDAC patients (Fig. 1a, b, Supplementary
Fig. 1a, Supplementary Table 1). These data suggest the defect in
BM progenitors is strongest and most consistent after progenitors
start to commit to the cDC lineage. We also analyzed cells of the
cDC subsets, cDC1s and cDC2s, found in the BM. Patient
populations showed a decrease in CD141+ cDC1s and CD1c+
cDC2s (Fig. 1a, b). As illustrated in Fig. 1a, CD141+ cDC1s are
rare in the BM but are dramatically reduced in BC and PDAC
patients. We validated these ﬁndings using a second cohort of BC
patients (Supplementary Fig. 1b). In contrast to the cDC lineage,
an expansion of BM immature granulocytes (CD11b
+CD33HiCD14-CD15+), potentially a subset of myeloid-derived
suppressor cells, was observed in both cancer types (Fig. 1b). This
result is in agreement with published observations in several other
solid tumor types8,32–35. To determine if the reduction in cDCs
extended into the periphery, where cDCs are thought to func-
tion13,18, we analyzed BC and PDAC patient blood samples and
found reduced pre-DC numbers and increased immature gran-
ulocyte numbers relative to healthy controls (Fig. 1c, Supple-
mentary Fig. 1c). We validated these ﬁndings in a second cohort
of PDAC patients (Supplementary Fig. 1d). Together, these data
suggest that cancer results in decreased cDC lineage cells in the
BM and decreases in the systemic pool of pre-DCs.
Previous studies have shown that CD141+ cDC1 numbers and
functions in the tumor are predictive of patient outcome1,3,36,
prompting us to assess whether changes in CD141+ cDC1s in the
BM prior to treatment or resection were also predictive of
response to therapy. We observed higher numbers of CD141+
cDC1s and lower numbers of granulocytes (CD45+CD11b+
CSF1R−CD15+CD14−) in the BM of BC patients who achieved
a pathological complete response (pCR) to neoadjuvant che-
motherapy (Fig. 1d, Supplementary Table 1). Notably, CD1c+
cDC2 numbers were not predictive of pCR, suggesting the
predictive nature is speciﬁc to the CD141+ cDC1 subset
(Supplementary Fig. 1e). These ﬁndings demonstrate that
tumor-induced decreases in CD141+ cDC1 development in the
BM could be an important indicator of patient immune
competency and response to therapy.
Local breast and pancreatic tumors systemically reduce cDC1s.
To more carefully study changes in cDC development during
cancer progression, we evaluated three distinct genetic mouse
models and four syngeneic orthotopic mouse models of BC and
PDAC. Similar to the human cancer patients, we found six of
these seven models had reductions in absolute numbers of BM
CD24+ cDC1s and most had reductions in the absolute number
of BM pre-DCs (Fig. 2a–c, Supplementary Fig. 3a–d). To further
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investigate the cDC lineage in tumor-bearing mice, we employed
PyMT-B6, a cell line derived from the genetic MMTV-Polyoma
Middle T (PyMT) mammary tumor mouse model on the C57BL/
6 background. Consistent with the patient data, mice bearing
end-stage orthotopic PyMT-B6 mammary tumors showed no
change in MDPs but a modest reduction in CDPs (Fig. 2b,
Supplementary Fig. 2a). This ﬁnding suggests that tumors impact
components of the cDC1 lineage. In contrast to cDC1s, Ly6G+
Ly6C+CSF1R+ immature granulocytes and Ly6G+CSF1R−
mature granulocytes expand in the BM (Fig. 2b, Supplementary
Fig. 2a). In addition, the changes in cDC progenitors and gran-
ulocytic populations were consistent in the genetic models of BC
and PDAC: MMTV-PyMT FvB/N and KPC (p48-Cre;LSL-
KrasG12D;Trp53ﬂox/+ C57BL/6), respectively (Supplementary
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Fig. 1 Human breast and pancreatic cancers reduce dendritic cell progenitors and CD141+ cDC1s. a Representative ﬂow cytometry gating strategy for
human BM pre-DCs, CD141+ cDC1s, and CD1c+ cDC2s, including representative ﬁnal plots from a BC patient and from a healthy control. b Frequency of
BM MDPs, CDPs, pre-DCs, CD141+ cDC1s, CD1c+ cDC2s, and immature granulocytes (CD11b+CD33HighCD14-CD15+) in baseline BC and PDAC patients
relative to healthy controls. Data from BC cohort 1 and PDAC cohort 1. Healthy controls n= 12; BC n= 10; PDAC n= 19. c Frequency of circulating blood
pre-DCs and immature granulocytes in baseline BC and PDAC patients relative to healthy controls. Data are from BC cohort 1 and PDAC cohort 1. Healthy
controls n= 12; BC n= 10; PDAC n= 17. d Frequency of BM CD141+ cDC1s and granulocytes (CD45+CD11b+CSF1R−CD15+CD14−), and the ratio of
cDC1s/granulocytes in BC patients prior to treatment or surgical intervention comparing those who achieved pathological complete response relative to
patients who did not achieve pathological complete response in BC cohort 2; n= 18. Additional cohorts illustrated in Supplementary Figure 1. Error bars
represent mean +/− s.e.m. or box plot; *p < 0.05, **p < 0.01, ***p < 0.001, n.s., not signiﬁcant by unpaired two-sided Student’s t test
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Fig. 3e, f). Unlike cDC1s, cDC2s were not consistently decreased
in the BM of tumor-bearing mice across several models
(Fig. 2a–c, Supplementary Fig. 3a–d). Together, these data suggest
that solid tumors reduce the number of cells that make up the
cDC lineage, including cDC1.
Speciﬁc reductions in the cDC progenitors and cDC1s suggest
a selective interruption of cDC1 development. Recent data show
that pre-DCs can commit to the cDC1 subset before leaving the
BM, rather than receiving inﬂuence from factors at a peripheral
site27,29,30. To evaluate this phenomenon, we assessed the number
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of DC1-committed pre-DCs (pre-cDC1s) in the BM using the
gating strategy deﬁned by Grajales-Reyes et al.29 employing the
Zbtb46-GFP mouse. We found that pre-cDC1s were decreased by
80% in the BM of tumor-bearing mice, which is a more
substantial decrease than the reduction in the broader pre-DC
population (Fig. 2d). These data suggest that tumors not only
reduce the number of cDC progenitors, but also reduce the
commitment of pre-DCs to the cDC1 lineage in the BM.
To determine if changes in cDC1 progenitors result in systemic
alterations in the pool of available cDCs, we analyzed circulating
pre-DCs. We found fewer pre-DCs and more granulocytes in the
blood of tumor-bearing mice relative to controls (Fig. 2e, f,
Supplementary Fig. 2b). Similar observations were seen in the
genetic BC model, MMTV-PyMT FVB/N, and genetic PDAC
model, KPC (Fig. 2g), as well as two additional orthotopic BC and
PDAC models (Supplementary Fig. 3b–c). These changes in the
pool of circulating pre-DCs correlated with reduced numbers of
CD103+ cDC1s in the uninvolved LNs of tumor-bearing mice
(Fig. 2h, Supplementary Fig. 2c). Congruent with observations in
BC and PDAC patients, these data show that mouse models of BC
and PDAC, independent of genetic driver and strain, have
systemically reduced numbers of cDC precursors and cDC1s.
Interestingly, pDCs were decreased in the BM, but circulating
pDCs were not decreased (Supplementary Fig. 3g), suggesting
they may be regulated differently.
Research has shown that cDCs turn over at a high rate in
tissues and require BM progenitors to provide new cDC117. To
determine if the decreased pool of circulating pre-DCs would
result in altered recruitment and antigen presentation at new sites
of inﬂammation, we measured the recruitment of CD103+ cDC1s
in the context of a tumor. PyMT-B6 mammary tumors were
established in the 4th lower mammary fat pads. Then, a matrigel
plug containing polyinosinic:polycytidylic acid (poly I:C) and
ovalbumin (OVA)-Texas Red (TxRd) conjugate was implanted in
the contralateral 2nd upper mammary fats pads of tumor-bearing
and control mice. We found that the presence of the primary
tumors resulted in decreased numbers of CD103+ cDC1s
recruited into the matrigel plug and decreased numbers of
migratory CD103+ cDC1s in the draining LN (Fig. 2i, Supple-
mentary Fig. 2d). These changes in cDC1 recruitment correlated
with reduced numbers of OVA-speciﬁc CD8+ T cells (CD3+CD8
+Dextamer+) in the matrigel plug (Fig. 2i). To verify that the
reduced number of cDC1s in the poly I:C plug was due to a
decreased pool of circulating pre-DCs rather than changes in
recruitment cytokines, we measured recruitment of CD103+
cDC1s to a matrigel plug containing the recruitment factor C-C
motif chemokine ligand 4 (Ccl4), which is known to be
downregulated in some tumor types26. Again, we saw a defect
in CD103+ cDC1s recruited to the Ccl4-containing matrigel plug
in tumor-bearing mice (Supplementary Fig. 3h). Similarly, we
found there was no change in pre-DC C-C motif chemokine
receptor 5 (Ccr5) expression in tumor-bearing mice (Supple-
mentary Fig. 3i). Together, these data suggest that tumor-induced
repression of cDC development results in a reduced pool of
circulating pre-DCs and a subsequent reduction in recruitment of
cDC1s to new sites of inﬂammation and impaired priming of
CD8+ T cells.
Tumors impair cDC1 developmental potential of progenitors.
The contrasting increases in granulocytes and decreases in cDC
progenitors led us to hypothesize that tumors alter the differ-
entiation potential of common myeloid precursor cells. To test
this, we isolated CD45.1+Lin−cKit+ScaI− myeloid progenitors
(MPs). This cell population maintains granulocyte, monocyte,
and cDC potential and contains granulocyte-macrophage pro-
genitors (GMPs)12. The MPs were transferred into tumor-free
controls or mice bearing PyMT-B6 tumors. We found that
CD45.1+ MPs transferred into tumor-bearing mice differentiated
into fewer CDPs, pre-DCs, and cDC1s in the BM, but more
granulocytes in both the BM and blood (Fig. 3a). Fewer CD8α+
cDC1s were included in the CD45.1+ products in the spleens of
tumor-bearing hosts. CD45.1+ granulocyte products did not
accumulate in the spleen of tumor-bearing mice relative to
tumor-free controls. Although CD45.1+ monocytes were not
consistently increased in each organ, they accumulated in the
spleen (Supplementary Fig. 4a). These data suggest that tumors
preferentially drive the differentiation of shared progenitors to
granulocytes at the expense of cDC1 development. To determine
if exposure to tumors in vivo programs BM progenitor cells to
resist cDC1 differentiation, we isolated MPs, MDPs, or CDPs
from tumor-free and PyMT-B6 tumor-bearing mice. When cul-
tured in FMS-like tyrosine kinase 3 ligand (Flt3L), we found MPs,
MDPs, and CDPs isolated from tumor-bearing mice were less
able to differentiate into cDC1s compared to those cells isolated
from tumor-free mice (Fig. 3b). Of these progenitors, CDPs
appeared to be most impaired in their capacity to differentiate
into cDC1s. Of note, MPs from tumor-bearing mice but not from
tumor-free mice differentiated into granulocytes even in the
absence of granulocyte differentiation factors (Supplementary
Fig. 4b). This result suggests MPs from tumor-bearing mice are
Fig. 2 Primary mammary and pancreatic tumors systemically decrease cDC1s. a Representative ﬂow cytometry gating strategy for mouse BM pre-DCs,
CD24+ cDC1s, and Sirpα+ cDC2s. b Number of BM MDPs, CDPs, pre-DCs, immature granulocytes, granulocytes, CD24+ cDC1s, and Sirpα+ cDC2 from
mice bearing end-stage orthotopic PyMT-B6 mammary tumors relative to tumor-free controls; n= 6/group. Data are representative of three independent
experiments. c Number of BM pre-DCs, CD24+ cDC1, and Sirpα+ cDC2 in end-stage genetically engineered mouse models (GEMM) of BC (MMTV-
PyMT) and PDAC (KPC) relative to tumor-free controls; tumor-free MMTV-PyMT controls n= 6; MMTV-PyMT, n= 6; tumor-free KPC controls, n= 7;
KPC, n= 8. d Alternative representative gating strategy using Zbtb46-GFP mice continued from Fig. 2a for BM committed pre-cDC1s, including
representative plots from tumor-free and PyMT-B6 tumor-bearing mice. Number of BM pre-cDC1s in Zbtb46-GFP+ mice bearing end-stage orthotopic
PyMT-B6 mammary tumors relative to tumor-free Zbtb46-GFP+ controls; n= 6/group. Data are representative of two independent experiments. e
Representative ﬂow cytometry gating strategy for mouse blood pre-DCs. f Number of blood pre-DCs and granulocytes from mice bearing end-stage
orthotopic PyMT-B6 mammary tumors relative to tumor-free controls; n= 6/group. Data are representative of three independent experiments. g Number
of blood pre-DCs in end-stage genetic mouse models of BC (MMTV-PyMT) and PDAC (KPC) relative to tumor-free controls, n= 7/group. h Number of
uninvolved LN CD103+ cDC1s from mice bearing end-stage orthotopic PyMT-B6 mammary tumors relative to tumor-free controls; n= 6/group. Data are
representative of two independent experiments. i Mice with 1.0 cm diameter orthotopic PyMT-B6 tumors and tumor-free controls were implanted with
matrigel plugs containing poly I:C+OVA-TxRd peptide in the upper mammary fat pad. Number of CD103+ cDC1s in the plug and draining LN and OVA-
speciﬁc CD8+ T cells (CD3+CD8+Dextamer+) in the plug 10 days after implant; n= 6/group. Data are representative of two independent experiments.
End-stage for each model is deﬁned in the Methods. Error bars represent mean +/− s.e.m.; *p < 0.05, **p < 0.01, ***p < 0.001, n.s., not signiﬁcant by
unpaired two-sided Student’s t test
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intrinsically primed to differentiate into granulocytes at the
expense of cDC1s. As expected, MDPs and CDPs from tumor-
free or tumor-bearing mice did not have granulocyte differ-
entiation potential (Supplementary Fig. 4b, c). Taken together,
these data suggest that tumors alter myeloid progenitor fate by
increasing their potential to differentiate into granulocytes at the
expense of cDC1 production.
To further investigate the differences in progenitors from
tumor-free and tumor-bearing mice, we proﬁled the gene
expression in GMPs, MDPs, and CDPs. We found GMPs, MDPs,
and CDPs from tumor-bearing mice failed to upregulate proteins
indicative of the cDC program (e.g., Irf8, Zbtb46, Cd209a, Spib,
Batf3, and Bcl11a). This result is in contrast to the increased
expression of markers indicative of a granulocyte or monocyte
CD45.1+ MP Bone marrow
0
2
4
6
8
Tumor-free host PyMT-B6 host 
MDPs CDPs Pre-DCs
*
**
**
Blood
Granulocytes
Tumor-free donor PyMT-B6 donor
%
 C
D4
5.
1
%
 C
D4
5.
1
%
 C
D4
5.
1
%
 C
D4
5.
1
***
**
%
 C
D4
5.
2
%
 C
D4
5.
2
0
1
2
3
*
%
 C
D4
5.
2
0
1
2
3
4
5
*
MPs        cDC1s MDPs       cDC1s CDPs        cDC1s
CD45.2+
MP, MDP, or CDP
H
ie
ra
rc
hi
ca
l c
lu
st
er
in
g
Tumor-free
 MDP
2.82
PyMT-B6 MDP PyMT-B6 CDP Tumor-freeCDP
R
el
at
iv
e 
ex
pr
es
sio
n
R
el
at
iv
e 
ex
pr
es
sio
n
Irf8
R
el
at
iv
e 
ex
pr
es
sio
n
R
el
at
iv
e 
ex
pr
es
sio
n
Tumor-free PyMT-B6
***
SpiBCd209a
Zbtb46
*
*
***
***
***
***
**
Cebpb
*
*
Gfi1
**
*
***
Cebpa
Cebpe
**
**
**
Id1
**
**
**
Mafb
*
Granulocytes
Dendritic cell identity Granulocyte/monocyte identity
R
el
at
iv
e 
ex
pr
es
sio
n
R
el
at
iv
e 
ex
pr
es
sio
n
R
el
at
iv
e 
ex
pr
es
sio
n
Batf3 Bcl11a
*
***
R
el
at
iv
e 
ex
pr
es
sio
n
%
 C
D4
5.
1
0
20
40
60
**
GMP MDP CDP
R
el
at
iv
e 
ex
pr
es
sio
n
***
GMP MDP CDP GMP MDP CDP
GMP MDP CDPGMP MDP CDP
GMP MDP CDP
GMP MDP CDP GMP MDP CDP
GMP MDP CDP
GMP MDP CDP
GMP MDP CDP
0
1
2
3
4
5
GMP MDP CDP
R
el
at
iv
e 
ex
pr
es
sio
n
R
el
at
iv
e 
ex
pr
es
sio
n
%
 C
D4
5.
1
Wild-type
BATF3–/–
BATF3–/– +Normal cDC progenitors
BATF3–/– +Tumor cDC progenitors
Days after implant
**
7 9 11 13 15 –2.82
R
el
at
iv
e 
ex
pr
es
sio
n
d
0.15
0.00
0.10
0.05
0.5
0.4
0.3
0.2
0.1
0.0
2.0
1.5
1.0
0.5
0.0
10
CD24+ cDC1s
CD45.1+
Bone marrow
feeder layer
+
Flt3L
2.5
2.0
1.5
1.0
0.5
0.0
2.0
1.5
1.0
0.5
0.0
0.025
0.020
0.015
0.010
0.005
0.000
0.5
0.4
0.3
0.2
0.1
0.0
0.08
0.06
0.04
0.02
0.00
0.0
Tu
m
or
 b
ur
de
n 
cm
3
0.6
0.4
0.2
0.25
0.00
0.20
0.15
0.10
0.05
0.05
0.04
0.03
0.02
0.01
0.00
1.0
0.8
0.6
0.4
0.2
0.0
0.20
0.15
0.10
0.05
0.00
0.08
0.06
0.04
0.02
0.00
0.20
0.15
0.10
0.05
0.00
2.0
0.0
1.5
1.0
0.5
0.020
0.015
0.010
0.005
0.000
a
b
c
e
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03600-6
6 NATURE COMMUNICATIONS |  (2018) 9:1250 | DOI: 10.1038/s41467-018-03600-6 |www.nature.com/naturecommunications
fate (e.g., Cebpe, Gﬁ1, Cebpa, Id1, Cebpb, and Mafb) (Fig. 3c). We
further proﬁled MDPs and CDPs from tumor-bearing mice by
microarray to look for global changes in gene expression. We
found the CDPs from tumor-bearing mice clustered closer with
MDPs than did CDPs from tumor-free mice (Fig. 3d, Supple-
mentary Tables 2, 3). DAVID (database for annotation,
visualization and integrated discovery) analysis showed that the
upregulated genes were enriched for biologic process terms like
inﬂammatory response, myeloid cell differentiation, cell cycle
regulation, and cytokine secretion, whereas downregulated genes
were enriched for biologic process terms like transcriptional
regulation, major histocompatibility complex (MHC) class II
protein complex binding, differentiation, and covalent chromatin
modiﬁcations (Supplementary Table 4). Overall, these data
suggest a failure in progenitors to upregulate the cDC program,
while favoring the granulocytic and monocytic programs in
tumor-bearing mice.
To determine if the reduction in cDC1 differentiation potential
could impact tumor immunity and tumor progression, we
measured the ability of progenitors isolated from tumor-bearing
or tumor-free mice to control tumor growth in BATF3−/− mice.
We chose BATF3−/− mice because they lack functional cDC1s18
but have no defect in granulocyte number (Supplementary
Fig. 4d). First, we observed that tumor growth of PyMT-mCh-
OVA, a variant of PyMT-B6 expressing antigenic mCherry and
ovalbumin, was restrained in wild-type, but not in BATF3−/−
mice (Fig. 3e). MDPs and CDPs were sorted from PyMT-B6
tumor-bearing or tumor-free controls and transferred into
BATF3−/− mice. The recipients were then implanted with
PyMT-mCh-OVA. Mice that received MDPs and CDPs from
wild-type mice were able to restrain PyMT-mCh-OVA tumor
growth, similar to wild-type mice, whereas mice that received
MDPs and CDPs from tumor-bearing mice were not able to
restrain tumor growth (Fig. 3e). These data suggest that
progenitors inﬂuenced by tumor burden are no longer able to
act as a source of cDC1s and thus fail to induce anti-tumor
immunity and control antigenic tumor progression.
Tumor-derived GCSF inhibits cDC1 development. To under-
stand which factors inhibit cDC development during cancer
progression, we proﬁled cytokines known to inﬂuence myeloid
and cDC differentiation in the blood and BM of tumor-bearing
mice. We found that both granulocyte colony-stimulating factor
(GCSF) and interleukin-6 (IL-6) were highly upregulated in the
blood of PyMT-B6 tumor-bearing mice relative to tumor-free
controls (Fig. 4a). Additionally, GCSF, but not IL-6, was upre-
gulated in the BM of tumor-bearing mice relative to controls
(Fig. 4a) and in the blood serum of BC patients (Fig. 4b). To
determine if either of these cytokines was necessary to alter cDC
differentiation, we neutralized both GCSF and IL-6 in the context
of PyMT-B6 tumors. As above, the presence of PyMT-B6 tumors
reduced BM pre-DC and CD24+ cDC1 and blood pre-DC
numbers while increasing granulocytes in both tissues. After
treatment with GCSF-neutralizing antibody, we observed that
pre-DCs and CD24+ cDC1s in the BM and pre-DCs in the blood
were restored to levels in tumor-free mice. This result suggests
that tumor-induced GCSF is necessary to reduce cDC1 numbers
in tumor-bearing mice. Additionally, GCSF neutralization
reduced immature granulocytes in the BM and granulocytes in
the blood, as expected32,37. Neutralization of GCSF was also
sufﬁcient to increase CD8+ T cells in the tumor (Fig. 4c).
Although IL-6 neutralization reduced immature granulocytes and
inﬂammatory monocytes as previously described38, it did not
reverse tumor-induced reductions in pre-DCs or CD24+ cDC1s
in the BM (Supplementary Fig. 5a).
To determine if GCSF alone is sufﬁcient to disrupt cDC
differentiation, we dosed mice with recombinant GCSF. We used
2 μg/day of recombinant GCSF to achieve steady-state serum
GCSF concentrations comparable to those in tumor-bearing mice
(Supplementary Fig. 5b). We found that changes in BM
progenitor numbers in tumor-free mice dosed with GCSF mice
paralleled those observed in tumor-bearing mice. These changes
included GCSF-induced reduction in MDPs, CDPs, pre-DCs, and
cDC1s in the BM and reduced pre-DCs in the blood as compared
to untreated mice (Fig. 4d). As expected, GCSF increased
immature granulocytes in the BM and granulocytes in the blood
(Fig. 4d). These data implicate a role for GCSF in reducing cDC1
numbers during cancer progression.
To determine if GCSF could act directly on cDC progenitors to
inhibit cDC1 differentiation, we cultured MPs, MDPs, and CDPs
isolated from tumor-free mice in the presence of Flt3L+/− GCSF.
As expected, Flt3L drove cDC1 differentiation in all cell types,
whereas GCSF prevented Flt3L-mediated cDC1 expansion, and in
MPs instead drove granulocyte differentiation (Fig. 4e). These
results are consistent across a wide range of Flt3L and GCSF
concentrations (Supplementary Fig. 5c). To understand if GCSF
alone could prime progenitors to become unresponsive to Flt3L-
mediated cDC differentiation, consistent with the ex vivo results
shown in Fig. 3b, progenitors were pre-treated with GCSF for 24
h prior to plating for differentiation in Flt3L. Pre-treatment with
GCSF inhibited cDC1 differentiation even in CDPs (Fig. 4f),
suggesting that GCSF can alter the ability of a progenitor to
respond to cDC differentiation cues even in progenitors lacking
granulocyte differentiation capacity. To ensure GCSF was able to
signal in cDC progenitors directly, we analyzed the expression of
the GCSF receptor, Csf3r, in vivo. We found that Csf3r was
expressed in GMPs, MDP, and CDPs and unmodiﬁed by the
Fig. 3 Tumor burden alters the fate of myeloid progenitors. a CD45.1+Lin−Sca1−cKit+ MPs were transferred into mice bearing 1.0 cm diameter orthotopic
PyMT-B6 tumors or tumor-free controls. BM was analyzed for CD45.1+ populations after 2 weeks. BM MDPs, CDPs, pre-DCs, CD24+ cDC1s, and
granulocytes, and blood granulocytes displayed as frequency of CD45.1; n= 5/group. b CD45.2+Lin−Sca1−cKit+ MPs, CD45.2+ MDPs, and CD45.2+
CDPs were isolated from end-stage orthotopic PyMT-B6 tumor-bearing or tumor-free donors. Progenitors were cultured on CD45.1+ BM feeder culture for
5 days in the presence of 100 ng/ml Flt3L. Final cultures were analyzed for cDC1 (Live CD45.2+CD45.1-MHCII+CD11c+Sirpα-CD24+). End stage is deﬁned
in the Methods. Data are representative of three independent experiments consisting of three wells per condition. GMPs, MDPs, and CDPs were sorted
from mice bearing end-stage orthotopic PyMT-B6 mammary tumors and tumor-free controls. c GMPs, MDPs, and CDPs were analyzed by RT-qPCR. d
MDPs and CDPs were analyzed by microarray. Cluster analysis was performed with a differential genes list generated from gene with 1.5-fold at p < 0.05
and FDR q < 0.05 in MDP or CDP comparison from PyMT-B6 tumor bearing to tumor free. Four samples, each consisting of two mice, were analyzed per
group. eMDPs and CDPs were isolated from PyMT-B6 tumor-bearing mice or tumor-free controls. Progenitors were adoptively transferred into BATF3−/−
mice. PyMT-mCh-OVA was implanted after 3 days into wild-type mice, BATF3−/− mice without adoptive transfer, and BATF3−/− mice with adoptive
transfer from tumor-free or tumor-bearing mice. Tumor growth was monitored. Error bars represent mean +/− s.e.m.; *p < 0.05, **p < 0.01, ***p < 0.001
by unpaired two-sided Student’s t test or two-way ANOVA
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presence of tumors (Supplementary Fig. 5d). Together, these data
suggest that tumor-induced GCSF is both necessary and sufﬁcient
to reduce cDC1 differentiation and can act directly on cDC
progenitors.
We next sought to determine the source of GCSF. First we
analyzed both tumor tissues and BM samples from the
transplantable PyMT-B6 and the genetic KPC models for Csf3
by in situ hybridization (ISH). We found that although BM cells
expressed Csf3, levels were not elevated by the presence of PyMT-
B6 and KPC tumors (Supplementary Fig. 5e). By contrast, tumor
tissues from PyMT-B6 and KPC models had higher Csf3 levels
compared to normal mammary and pancreas tissues (Fig. 5a). We
also observed that the majority of the Csf3 ISH signal was present
in the tumor cells and not the stroma (Fig. 5a). To verify this
result in human BC and PDAC tissues, we stained for GCSF
protein by immunohistochemistry (IHC). Similar to our mouse
models, we found that GCSF was highly expressed in breast and
pancreas tumor tissues (Fig. 5b). Additionally, although GCSF
was expressed in both tumor and stroma, tumor levels of GCSF
were considerably higher than stroma levels in most cases.
Together, these data suggest that tumor-derived GCSF may be a
dominant source of GCSF in tumor-bearing animals. To directly
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test if tumor-derived GCSF was responsible for impaired cDC
development, we deleted the Csf3 gene using CRISPR CAS9 in the
PyMT-B6 cell line (PyMT-B6 GCSFKO). Both BM and blood
proﬁling showed pre-DCs and cDC1 populations were recovered
and immature granulocytes were reduced in PyMT-B6 GCSFKO
tumor-bearing mice relative to PyMT-B6 tumor-bearing controls
(Fig. 5c). These results were repeated with a second independent
clone (Supplementary Fig. 5f). These data demonstrate that GCSF
derived from tumor cells is impairing cDC1 differentiation.
GCSF inhibits cDC1 development by impairing IRF8 expres-
sion. Research has shown that GCSF preferentially expands
immature granulocytes and monocytes by suppressing IRF8
expression through activation of signal transducer and activator
of transcription 3 (STAT3) in granulocytic-monocytic pre-
cursors39,40. Because IRF8 is an important transcription factor for
cDC1 development, we hypothesized GCSF might drive reduced
IRF8 expression in cDC progenitors leading to impaired cDC1
differentiation19,41,42. In support of this notion, our expression
proﬁling demonstrated that Irf8 messenger RNA (mRNA) was
downregulated in cDC progenitors from tumor-bearing mice
(Fig. 3c). Additionally, we found IRF8 protein was reduced in
tumor-bearing mouse MDPs, CDPs, and pre-DCs (Fig. 6a).
Further, we analyzed IRF8 target gene expression in GMPs,
MDPs, and CDPs and found that, relative to controls, tumor-
bearing mice had decreased mRNA expression of multiple MHC
molecules, as well as TapBP, Tap2, Batf3, and Pml (Figs. 3c, 6b).
In contrast, Id2, another regulator of cDC1 development, was not
reduced (Supplementary Fig. 6a)17. To understand if down-
regulation of IRF8 is responsible for some of the gene expression
changes in the microarray analysis (Fig. 3d), differentially
expressed genes between control and tumor-bearing mice were
compared to genes that are differentially expressed in IRF8−/−
myeloid progenitors39,41. We found tumor-regulated genes were
enriched for genes regulated in IRF8−/− myeloid progenitors
(Supplementary Fig. 6b). In keeping with the ability of GCSF to
downregulate IRF8 through STAT3 activation39, we observed that
phosphorylated STAT3 (pSTAT3) was elevated in MDPs, CDPs,
and pre-DCs from tumor-bearing mice (Fig. 6c).
To determine if these changes also occur in human cancer
patients, we analyzed IRF8 expression in human BM and found
that IRF8 was downregulated in both BC and PDAC patients
compared to healthy controls (Fig. 6d). Additionally, the extent of
IRF8 downregulation correlated with the decrease in BM pre-DCs
in patients (Fig. 6e). We also found IRF8 expression was
decreased in the blood pre-DCs of pancreatic cancer patients
(Fig. 6f) and the extent of IRF8 downregulation correlated with
blood pre-DC numbers (Fig. 6g). Because IRF8 is a molecular
marker of pre-DCs committed to the cDC1 lineage, these data
also suggest that patients have reduced numbers of circulating
pre-cDC1s relative to healthy controls. We next assessed if
downregulation of IRF8 in circulating pre-DCs impacted patient
outcome and found patients with low IRF8 expression in
circulating pre-DCs had decreased recurrence-free and overall
survival (Fig. 6h). These results suggest that IRF8 expression is
modulated in human cancers and may be an indicator of cDC1
development and patient outcome.
To conﬁrm that GCSF was upstream of IRF8 suppression, we
measured IRF8 expression in cDC progenitors from tumor-
bearing mice following GCSF neutralization. We found IRF8
expression was recovered in the MDP, CDP, and pre-DCs
following anti-GCSF immunoglobulin G (IgG) treatment (Fig. 7a).
Furthermore, IRF8 expression was, again, downregulated in
progenitors from PyMT-B6 tumor-bearing mice but was not
downregulated in progenitors from PyMT-B6 GCSFKO mice
(Supplementary Fig. 6c). To show GCSF was acting directly on
progenitors to modulate IRF8 expression, we treated MPs, MDPs,
and CDPs alone in vitro with GCSF or GCSF+Flt3L. We found
Irf8, as well as its target gene Batf3, were downregulated in both
conditions relative to controls (Fig. 7b). Interestingly, Flt3L
treatment did not drive IRF8 expression above controls
(Supplementary Fig. 6d), suggesting Flt3L and GCSF act through
different mechanisms to modulate cDC1 differentiation. To
determine if downregulation of IRF8 is necessary for GCSF to
impair cDC1 differentiation, we investigated if IRF8 overexpres-
sion would make MPs insensitive to GCSF. Without IRF8
overexpression, GCSF drove down Flt3L-mediated cDC1 differ-
entiation, similar to the results shown in Fig. 4e. However, IRF8
overexpression rendered MPs insensitive to GCSF, and their
cDC1 differentiation was comparable to Flt3L-alone conditions
(Fig. 7c). These data suggest GCSF must modulate IRF8
expression to impact cDC1 differentiation.
IRF8 and cDC1s support anti-tumor CD8+ T-cell responses.
To determine whether suppression of cDC1 differentiation was
detrimental to anti-tumor immunity, we measured tumor-speciﬁc
T-cell activation in the presence or absence of an established
tumor. To accomplish this, PyMT-B6 tumors, referred to here as
the primary tumor, were established in the lower mammary fat
pad. A secondary tumor using the PyMT-mCh-OVA cell line was
then implanted into the upper mammary fat pad of the same
mouse. We observed reduced recruitment of CD103+ cDC1s to
the secondary tumor site and draining LNs of primary tumor-
bearing mice (Fig. 8a). This result is consistent with the reduction
in the available pool of circulating pre-cDC1s in tumor-bearing
animals (Fig. 2i). To test if reduced recruitment of CD103+
cDC1s was functionally relevant, we measured OVA-speciﬁc
CD8+ T cells within the secondary tumor site and the secondary
tumor-draining LNs and found the OVA-speciﬁc CD8+ T cells
Fig. 4 GCSF disrupts cDC1 differentiation. a Blood and BM serum cytokines in orthotopic PyMT-B6 end-stage tumor-bearing mice relative to tumor-free
controls; tumor-free, n= 6; PyMT-B6, n= 7. b GCSF in human BC patient blood serum relative to healthy controls; healthy controls, n= 30; BC, n= 42. c
Number of BM pre-DCs, CD24+ cDC1s, and immature granulocytes; numbers of blood pre-DCs and granulocytes, and tumor CD8+ T cells (CD45+CD3
+CD8+) in tumor-free mice, orthotopic PyMT-B6 tumor-bearing end-stage mice, and orthotopic PyMT-B6 tumor-bearing end-stage mice treated for
2 weeks with 50 μg anti-GCSF IgGs 3 × /week; n= 5–7/group. Data are representative of two independent experiments. d Number of BM MDPs, CDPs,
pre-DCs, CD24+ cDC1s, and immature granulocytes, and number of blood pre-DCs and granulocytes in C57BL/6 mice treated with 2 μg GCSF for 10 days;
n= 6/group. Data are representative of two independent experiments. e CD45.2+Lin−Sca1−cKit+ MPs, MDPs, and CDPs isolated from tumor-free mice
were cultured on CD45.1+ BM feeder culture in the presence of 100 ng/ml Flt3L, 100 ng/ml GCSF, or 100 ng/ml Flt3L and 100 ng/ml GCSF for 5 days.
Final cultures were analyzed for cDC1s (Live CD45.2+CD45.1-MHCII+CD11c+Sirpα-CD24+) and granulocytes (Live CD45.2+CD45.1-CD11b+Ly6G+). Data
are representative of three independent experiments consisting of three wells per condition. f Experiment similar to that in Fig. 4d, but CD45.2+ cells were
pre-treated with 100 ng/ml GCSF or media alone for 24 h prior to plating on CD45.1+ BM feeder layer. Data are representative of two independent
experiments consisting of three wells per condition. End stage for each model is deﬁned in the Methods. Error bars represent mean+/− s.e.m. or box plot;
*p < 0.05, **p < 0.01, ***p < 0.001 by unpaired two-sided Student’s t test
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were reduced in both sites of primary tumor-bearing mice
compared to controls (Fig. 8a). To speciﬁcally implicate IRF8 and
cDC1s in this decreased CD8+ T-cell response, we employed
IRF8−/− and Batf3−/− mice, both of which have impaired cDC1
differentiation18,19,42. In these knockouts, we observed reduced
numbers of tumor-speciﬁc CD8+ T cells comparable to the
primary tumor-bearing mice. In addition, this reduction was not
further decreased by the presence of primary tumors (Fig. 8a).
These data suggest that tumor-induced reductions in cDC1
development have a functional consequence on tumor-speciﬁc
CD8+ T-cell responses that could contribute to reduction in anti-
tumor immunity.
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Tumor-induced reductions in IRF8 also expand immature
granulocytes that are known to have immune-suppressive
functions and can otherwise promote tumor progression8,37,43.
We sought to determine the contributions of immature
granulocyte expansion to reduced number of cDC1s and reduced
anti-tumor CD8+ T-cell responses. To test if cDC1 depletion was
regulated through granulocyte expansion, mice were treated with
anti-Ly6G IgGs. Ly6G-depletion did not reverse the defect in BM
pre-DCs and cDC1s and did not recover IRF8 expression in BM
progenitors (Supplementary Fig. 7a). To show that immature
granulocytes were not mediating CD8+ T-cell suppression
beyond the loss of cDC1s in this model, we neutralized Ly6G
in the context of the secondary tumor experiment described
above. We found Ly6G depletion did not recover tumor-speciﬁc
CD8+ T cells in the secondary tumor nor the draining LN
(Fig. 8a). Similarly, we showed anti-Ly6G depletions did not
recover CD103+ cDC1 recruitment to a matrigel plug containing
poly I:C and OVA-TxRd conjugate, a secondary site of
inﬂammation, in primary tumor-bearing mice. Additionally,
CD103+ cDC1s were not recovered in the draining LN and
OVA-speciﬁc CD8+ T cells were not recovered in the matrigel
plug (Supplementary Fig. 7b). To test whether the loss of IRF8
had a functional consequence on tumor outgrowth by acting
through the loss of cDC1s rather than the expansion of
granulocytes, we measured the growth of PyMT-mCh-OVA
tumors in IRF8−/− mice, which lack cDC1s and have expanded
granulocytes, and Batf3−/− mice, which only lack functional
cDC1 (Supplementary Fig. 7c)18,41. We found that tumors grew
at the same rate in Batf3−/− as IRF8−/− mice, but that this rate
was faster than wild-type controls (Fig. 8b). Also, we neutralized
Ly6G in IRF8−/− mice and measured PyMT-mCh-OVA tumor
growth and found tumors grew at similar rates (Fig. 8c). These
ﬁndings suggest that the loss of IRF8 can promote tumor growth
by suppressing cDC1s rather than solely through the expansion of
granulocytes. Together, these results show granulocytes do not act
as an intermediate to inhibit cDC1 differentiation and the
functional effects on antigen speciﬁc CD8+ T cells and tumor
control are primarily mediated by cDC1s, not granulocytes, in
this model.
GCSF neutralization overcomes resistance to immunotherapy.
Our data suggest that exposure to tumor-derived GCSF can
impair BM progenitors in their ability to generate cDC1s. As
Flt3L therapy has been developed for use in patients to bolster
cDC numbers and function2, we asked if the impairment in cDC
development could be rescued by Flt3L treatment in vivo or if
GCSF neutralization was necessary for maximum efﬁcacy of this
therapy. To accomplish this we treated tumor-free or mice
bearing a 1 cm+ diameter PyMT-B6 tumor with Flt3L+/− anti-
GCSF IgGs for 2 weeks. Consistent with previous reports2, we
observed that in tumor-free mice treated with Flt3L expanded
pre-DCs, cDC1, and cDC2 in the BM and pre-DCs in the blood
(Fig. 9a, b). We also observed that combined treatment with Flt3L
and anti-GCSF IgGs did not further upregulate pre-DC or cDC
numbers in tumor-free mice (Fig. 9a, b). This result is consistent
with the ﬁnding that GCSF is expressed at lower levels under
non-pathologic conditions (Fig. 4a). Similar to our other
experiments, pre-DC and cDC1 numbers were decreased in the
BM and blood of PyMT-B6 tumor-bearing mice compared to
controls (Fig. 9a, b). We also found that although Flt3L could
expand pre-DC and cDC numbers in the BM and blood in the
presence of tumors, this expansion was limited compared to
tumor-free mice in that pre-DC or cDC1 numbers only reached
levels comparable to untreated tumor-free mice (Fig. 9a, b). These
data suggest that BM progenitors in tumor-bearing mice are
resistant to Flt3L-induced cDC1 differentiation, which is con-
sistent with our in vitro results (Fig. 3b). Furthermore, anti-GCSF
IgGs and Flt3L synergized to recover pre-DC and cDC1 numbers
in tumor-bearing mice (Fig. 9a, b). Because our data suggest that
GCSF impacts IRF8 levels, we analyzed the impact of Flt3L and
anti-GCSF IgGs on IRF8 levels in DC progenitors. In tumor-
bearing mice, in which IRF8 is downregulated, neutralizing GCSF
restores IRF8 levels to tumor-free mouse conditions in BM pro-
genitors. Importantly, neutralizing GCSF also increased IRF8
levels in pre-DCs (Fig. 9c, Supplementary Fig. 7d). These ﬁndings
suggest neutralizing tumor-induced GCSF is required to recover
IRF8 expression, which is necessary for cDC1 differentiation.
To determine if these changes in lymphoid tissues translated to
increased tumor immunity, we analyzed tumor tissues. As
previously reported2, Flt3L increases both tumor-inﬁltrating
CD103+ cDC1s and CD11b+ cDC2s, but this expansion of
cDC1s was modest in this model (Fig. 9d). When Flt3L was
combined with anti-GCSF IgGs, tumor inﬁltration of CD103+
cDC1s, but not CD11b+ cDC2s, were increased by more than
twofold and this increase correlated with substantially more CD8
+ T cells. Together, these data show that GCSF neutralization
supports Flt3L-mediated expansion and mobilization of cDC1
and suggest this activity is facilitated in part by restoring IRF8
expression and commitment to the cDC1 lineage.
Given these results, we hypothesized Flt3L+anti-GCSF IgGs
would bolster cDC-based immunotherapeutic strategies in
established tumors. We employed poly I:C, which supports
cDC maturation, and anti-programmed cell death protein 1
(PD1) IgGs, which block a T-cell checkpoint. Mice bearing well-
established 1 cm+ diameter PyMT-B6 tumors were treated with
Flt3L+poly I:C+anti-PD1 IgGs+/−anti-GCSF IgGs. Mice treated
with combined Flt3L+poly I:C+anti-PD1 IgGs did not have an
increase in survival relative to vehicle-treated controls. By
contrast, survival was extended in mice treated with anti-GCSF
IgGs+Flt3L+poly I:C+anti-PD1 IgGs compared with mice
treated with vehicle alone or Flt3L+poly I:C+anti-PD1 IgGs
Fig. 6 IRF8 expression is reduced during breast and pancreatic cancer. a IRF8 measured in BM MDPs, CDPs, and pre-DCs of end-stage orthotopic PyMT-
B6 tumor-bearing mice and tumor-free controls; n= 7/group. Data are representative of three independent experiments. b RT-qPCR analysis of BM GMPs,
MDPs, and CDPs sorted from mice bearing end-stage orthotopic PyMT-B6 mammary tumors and tumor-free controls for IRF8 target genes, four samples
consisting of two mice each were analyzed per group. c pSTAT3 measured in BM MDPs, CDPs, and pre-DCs of end-stage orthotopic PyMT-B6 tumor-
bearing mice and tumor-free controls; n= 6. Data are representative of two independent experiments. d IRF8 expression in total BM from BC and PDAC
patients relative to healthy controls; n= 10/group. Data are from BC cohort 1 and PDAC cohort 1. e Correlation between BM pre-DCs and BM IRF8
expression in BC and PDAC patients. Data are from BC cohort 1 and PDAC cohort 1; n= 20. f IRF8 expression in blood pre-DCs from PDAC patients
relative to healthy controls; healthy controls n= 10, PDAC n= 43. Data are from PDAC cohort 2. g Correlation between blood pre-DCs and blood pre-DC
IRF8 expression in PDAC patients; n= 43. Data are from PDAC cohort 2. h Kaplan–Meier estimate of recurrence free survival and overall survival of
patients +/− median blood pre-DCs IRF8 expression. Log-rank (Mantel–Cox) p value is denoted for differences in recurrence-free survival and overall
survival. Data are from PDAC cohort 2. Spearman’s correlation (r2, correlation coefﬁcient). End stage for each model is deﬁned in the Methods. Error bars
represent mean +/− s.e.m or box plot; *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired two-sided Student’s t test
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(Fig. 9e, Supplementary Fig. 7e). This effect was not seen in
similarly treated IRF8−/− and BATF3−/− mice, suggesting that
this treatment is reliant on IRF8 and cDC1 activity (Fig. 9e,
Supplementary Fig. 7e). Together, these data suggest that GCSF
signaling may need to be inhibited to employ immunotherapy
effectively in some established tumor settings.
Discussion
Breast and pancreas cancers have had limited responses to single
agent immunotherapy in the clinic44–47. Although this limited
response might be explained in part by poor antigenicity, BC and
PDAC are also known to expand systemic populations of
immune-suppressive myeloid cells by increasing differentiation
from myeloid progenitors in the BM7,8,44. Our ﬁndings suggest
that tumor-induced inﬂammatory cytokines expand potentially
immune-suppressive myeloid cells and simultaneously suppress
anti-tumor cDC1 development from BM progenitors. Beyond
committing to the granulocyte, monocyte, or cDC lineages, cDC
progenitors further commit to the cDC1 subset before leaving the
BM27–30. These ﬁndings suggest that the antigen-presenting
capacity can be deﬁned before cells trafﬁc into the periphery and
is not entirely reliant on cues experienced at the tumor site.
Therefore, it is important to understand how tumors alter BM
myeloid differentiation to overcome tumor-induced immune
surveillance. Others have shown suppression of the transcription
factor IRF8 during tumor progression expands the immature
granulocyte and monocyte populations that are known to sup-
press anti-tumor immune responses39–41. We further demon-
strated IRF8 downregulation during cancer reduces cDC1
development in the BM. This is an important ﬁnding because
IRF8 expression in progenitors as early as the hematopoietic stem
cell primes transcriptional networks and inﬂuences lineage bias
towards cDC and cDC1 fate48,49. Additionally, tumor-induced
depletion of cDC1s has a functional implication on anti-tumor
immunity beyond the effect of granulocyte expansion. Even in the
context of granulocyte depletion, reduced cDC1 differentiation
inhibits CD8+ T cell-mediated anti-tumor responses, leading to a
loss of tumor control in this model. Given that previous work has
shown granulocyte depletion is sufﬁcient to recover anti-tumor
immunity in some cases9,50–53, we speculate there is a balance
between the expansion of granulocytes as immune suppressors
and depletion of cDC1s as immune stimulators that varies with
tumor type, disease progression, and tumor models. In addition
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+CD45.1-MHCII+CD11c+Sirpα-CD24+). Data are representative of three independent experiments consisting of three wells per condition. Error bars
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to the BM differentiation effect we have identiﬁed, reduced IRF8
expression is also detrimental to cDC maturation following
activation signals in the periphery because IRF8 regulates a
multitude of genes involved with antigen presentation and
expression of interleukin 12 (IL-12)19,54. Together, these results
suggest tumors can shift the net balance of immune-stimulatory
and immune-suppressive BM and peripheral myeloid cells via
alteration of IRF8 expression through regulation of inﬂammatory
cytokines like GCSF, thereby blunting anti-tumor immunity.
Though granulocyte–monocyte expansion in BC and PDAC
has been shown to impede tumor immune surveillance7–9, it is
important to consider the role of cDC1s in orchestrating anti-
tumor CD8+ T-cell responses. In these studies, the presence of
primary tumors is sufﬁcient to reduce the pool of pre-cDC1s and
interrupt tumor-speciﬁc CD8+ T-cell expansion. The number of
CD8+ T cells in the tumor environment is important for response
to both chemotherapy and immunotherapy3,55–58. cDC1s are
known to regulate CD8+ T-cell numbers and function in the
tumor environment. To this end, cDC1s cross-present tumor-
associated antigen to reactivate CD8+ T cells within tumor tissues
and transport antigen to the draining LNs, where they stimulate
naive T cells2,6,18,20,22,23. Intratumoral cDC1s also recruit T cells
from the LNs into the tumor by expressing C-X-C motif che-
mokine ligand 9/10 (CXCL9/10)21,26. Furthermore, memory T-
cell responses are deﬁcient in mice depleted of cDC1s, suggesting
cDC1s are important for re-challenge, which could manifest at
the time of metastasis or tumor recurrence in patients21. Toge-
ther, these functions identify cDC1s as critical supporters of anti-
tumor CD8+ T cells. Given cDC1 differentiation is interrupted in
cancer, our study shows that there is no longer a sufﬁcient supply
of cDC1 progenitors available to populate new and persistent sites
of inﬂammation, such as sites of tumor outgrowth and metastasis,
and that this lack of cDC1s is detrimental to anti-tumor CD8+ T-
cell responses.
Through their function in supporting CD8+ T-cell responses,
cDC1s are important for tumor control and response to therapies.
In agreement with these data, others have shown that cDC1s are
required for tumor control at both primary and metastatic
0.0
0.1
0.2
0.3
0
5
10
15
0.00
0.05
0.10
0.15
0
2
4
6
8
10
0.0
0.1
0.2
0.3
0.4
0.00
0.05
0.10
0.15
0.20
0.25
0 5 10 15 20 25
0.0
0.5
1.0
1.5
0 5 10 15 20 25
0.0
0.5
1.0
1.5
2.0
2.5
0
5
10
15
0.0
0.1
0.2
0.3
Wild-type
PyMT-mCh-OVA 
%
 T
ot
al
*
%
 C
D8
+ 
T 
ce
lls
OVA-Specific CD8+ T cells
*
**
Se
co
nd
ar
y
 
tu
m
or
D
ra
in
in
g
lym
ph
 n
od
e
%
 T
ot
al
*
%
 C
D8
+ 
T 
ce
lls
*
%
 T
ot
al
***
%
 T
ot
al
**
OVA+ secondary
tumor
Primary tumor
Wild-type
IRF8–/–
BATF3–/–
Days after implant
Tu
m
or
 b
ur
de
n 
cm
3
Tu
m
or
 b
ur
de
n 
cm
3
***
n.s.
Primary tumor
IRF8–/– BATF3–/–
+–
–
+
+
Primary tumor + + +
+ + +
Primary tumor
+
––
––
––
––
IRF8–/– BATF3–/–
+Primary tumor + + +
+ + +
Primary tumor
+
––
––
––
––
Days after implant
IRF8–/–
IRF8–/– anti-Ly6G IgG
PyMT-mCh-OVA
***
n.s.
Anti-Ly6G IgG
Primary tumor +– +
+––
*
Anti-Ly6G IgG
Primary tumor +– +
+––
%
 T
ot
al
%
 C
D8
+ 
T 
ce
lls
*
Primary tumor
CD103+ cDC1sa
b c
Fig. 8 IRF8 and cDC1s are necessary for anti-tumor CD8+ T-cell responses. a Mice with 1.0 cm diameter orthotopic PyMT-B6 tumors and tumor-free
controls were implanted with PyMT-B6-mCh-OVA cells in the upper mammary fat pad. After 7 days, the secondary tumor and its draining LN were
analyzed for frequency of CD103+ cDC1s and OVA-speciﬁc CD8+ T cells. OVA-speciﬁc T-cell analysis was also performed in age-matched IRF8−/− and
Batf3−/− mice and mice treated with anti-Ly6G IgGs starting 1 day before implant of upper mammary fat pad tumor; n= 5 mice/group. Experimental
replicates are displayed. b Tumor volume over time in Batf3−/−, IRF8−/−, and wild-type controls implanted with orthotopic PyMT-B6-mCh-OVA tumors;
wild-type, n= 10; BATF3−/−, n= 7; IRF8−/− n= 4. Data are representatives of two individual experiments. c Tumor volume over time in IRF8−/−, IRF8−/−
treated with anti-Ly6G IgGs starting 1 day prior to implant and wild-type controls implanted with orthotopic PyMT-B6-mCh-OVA tumors; wild type, n= 6;
IRF8−/−, n= 3; IRF8−/− treated with anti-Ly6G IgGs, n= 3. Error bars represent mean +/− s.e.m.; *p < 0.05, **p < 0.01, ***p < 0.001, n.s., not signiﬁcant
by unpaired two-sided Student’s t test or two-way ANOVA
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03600-6
14 NATURE COMMUNICATIONS |  (2018) 9:1250 | DOI: 10.1038/s41467-018-03600-6 |www.nature.com/naturecommunications
sites1,18,24,43 Furthermore, cDC1s are required for responses to
checkpoint immunotherapy, and increased cDC1 numbers
improve the response to chemotherapy in some cancer mod-
els2,3,25,26,59. Others have shown that the number of CD141+
cDC1s in the tumor, especially in balance with immune-
suppressive myeloid cells, is an important indicator of che-
motherapy response and outcome in patients1,3,8,36. We found
that increased BM CD141+ cDC1 levels, in balance with reduced
BM granulocytes, correlate with pCR in BC patients undergoing
neoadjuvant chemotherapy. These data suggest tumor-induced
alteration in myeloid differentiation, and speciﬁcally cDC1
development occurring in the BM, may also impact patient
response to therapy and predict patient outcome. Reduced IRF8
expression in the tumor as a marker of cDC1s is correlated with
worse patient outcome1,3. Extending upon this ﬁnding, we found
reduced IRF8 expression in circulating pre-DCs also correlates
with reduced overall and recurrence-free survival in pancreatic
cancer patients. Given our new understanding of how tumors
employ IRF8 downregulation to alter myeloid differentiation, it
would be interesting to know if IRF8 expression in the BM or
blood of patients could be a novel biomarker of a patient’s
immune status and/or response to chemotherapy and
immunotherapy.
cDC1s are rare in the tumor microenvironment, and herein we
showed that cDC1s are limited during development in the BM by
tumor-induced inﬂammatory cytokines like GCSF1,2,60. To
improve adaptive immune responses against the tumor, especially
in the context of immunotherapies and chemotherapies, we
should consider strategies to bolster cDC1 BM development.
Others have also shown that Flt3L treatment or colony-
stimulating factor 1 (CSF1) neutralization expands cDC1 num-
bers in the tumor and increases response to both chemotherapies
and immunotherapies2,3. These strategies likely impact BM cDC1
differentiation and undermine this newly identiﬁed mechanism of
tumor immune evasion. Here, we neutralized GCSF to increase
BM cDC1 differentiation, which was able to further increase the
efﬁcacy of Flt3L by reﬁning the IRF8-mediated cDC1 differ-
entiation program. It is important to understand the interactions
between cytokines and BM myeloid development so we can better
modulate the systemic myeloid environment. These strategies
could then be used in patients to support anti-tumor immunity
and response to therapy.
In summary, we have shown that BC and PDAC alter the
balance of immune-stimulatory cDC1s versus immune-
suppressive myeloid cells by regulating IRF8 expression. This
process leads to a favorable immune environment for tumor
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end-stage mice treated with 50 μg anti-GCSF IgGs 3 × /week for 2 weeks and/or 30 μg Flt3L daily for 9 days. End stage is deﬁned in the Methods. a
Number of BM pre-DCs, CD24+ cDC1s, and Sirpα+ cDC2s. b Number of blood pre-DCs and granulocytes. c IRF8 measured in BM MDPs, CDPs, and pre-
DCs. d Number of tumor CD103+ cDC1s, CD11b+ cDC2s, and CD8+ T cells (CD45+CD3+CD8+); n= 6/group. e Established 1 cm+ diameter orthotopic
PyMT-mCh-OVA mammary tumors were treated with vehicle or Flt3L (30 μg)+anti-PD1 IgGs (200 μg)+intratumoral Poly I:C (50 μg)+/− anti-GCSF IgGs
(50 ng) according to the displayed treatment schedule. Survival to 2.3 cm3 tumor volume. Error bars represent mean +/− s.e.m.; *p < 0.05, **p < 0.01, ***p
< 0.001, n.s., not signiﬁcant by unpaired two-sided Student’s t test. Log-rank (Mantel–Cox) p value is denoted for differences in survival
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03600-6 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:1250 | DOI: 10.1038/s41467-018-03600-6 |www.nature.com/naturecommunications 15
progression. This mechanism reveals potential new biomarkers of
immune response and targets for combination therapies.
Methods
Human bone marrow, peripheral blood and tumor samples. BM and peripheral
blood were obtained from patients diagnosed with locally advance or unresectable
pancreatic ductal adenocarcinoma or clinical stage II/III breast cancer at the
Barnes-Jewish Hospital (St. Louis, MO, USA) from 2004 to 2014 and were followed
for recurrence and survival in a prospectively collected database. Samples were
collected under informed consent in concordance with Institutional Review Board
(IRB) approval (IRB protocol numbers 201102244, 201101961, 201108117). At the
time of collection, these patients had received no prior cancer-related treatment.
Healthy donor BM and blood were collected from cancer-free volunteers. Blood
was collected into vacuum tubes containing heparin or ethylenediaminetetraacetic
acid (EDTA) (BD Bioscience). Cells were isolated by ﬁcoll-density centrifugation
and frozen in fetal bovine serum with 5% dimethyl sulfoxide. BM from PDAC
patients and BC cohort 1 patients was isolated as previously described61,62. BM
from patients in BC cohort 2 was similarly obtained and stored but was not
subjected to ﬁcoll-density centrifugation. Breast tumor biopsies were from patients
at the time of metastatic diagnosis under informed consent in concordance with
IRB approval (IRB protocol number 201102394). Primary pancreatic adenocarci-
noma tissues were collected during surgical resection and veriﬁed by standard
pathology (IRB protocol number 201108117).
Cell lines and constructs. The PyMT-B6 murine mammary tumor cell line was
derived from the mammary tumor tissue obtained from an end-stage MMTV-
PyMT C57BL/6 mouse by our laboratory. The cell line was validated for PyMT
expression; pan-keratin positivity; and Vimentin, smooth muscle actin, and CD45
negativity. A subset of this cell line was labeled with click beetle red luciferase-
mCherry reporter and transduced to express OVA (PyMT-mCh-OVA). PyMT-B6-
GCSFKO was made using the lentiCRISPR v2 vector. Virus was packaged using
293T cells and helper plasmids pCMV-DR8.2 and pCMV-VSVG. Csf3 gRNA
sequences used were aggacgagaggccgttcccc, ctacaagctgtgtcaccccg, and gga-
gacggctcgccttgctc. Clones were selected and screened by sequencing for depletion of
the Csf3 gene. The 4T1-FL-GFP murine mammary tumor cell line was obtained
from Dr. Katherine Weilbaecher’s laboratory, originally from Dr. David Piwnica-
Worms (Washington University in St. Louis, MO, USA). It had been previously
modiﬁed to express ﬁreﬂy luciferase and green ﬂuorescent protein, as previously
described63. The Pan02 murine pancreatic tumor cell line was obtained from Dr.
David C. Linehan (University of Rochester, NY, USA). The KP 1.0 murine pan-
creatic tumor cell line was derived from the pancreatic tumor tissue obtained by
our laboratory from an end-stage KPC mouse and has been previously reported64.
All cell lines were maintained in Dulbecco’s modiﬁed Eagle's medium (DMEM)
(Lonza) supplemented with 10% fetal bovine serum (Atlanta Biological) and
penicillin/streptomycin (Gibco). All cell lines tested negative for mycoplasma.
Genetic and orthotopic mouse models. Mice were maintained in the Washington
University Laboratory for Animal Care barrier facility. All studies were approved
by the Washington University School of Medicine Institutional Animal Studies
Committee. MMTV-PyMT FVB/N were obtained from The Jackson Laboratory
and have been previously described65. Mice were analyzed at end stage, deﬁned as
approximately 3 months of age or when tumors reached >1.5 cm diameter. KPC
(p48-Cre;LSL-KrasG12D;Trp53ﬂox/+ C57BL/6) and KPPC (p48-Cre;LSL-KrasG12D;
Trp53ﬂox/ﬂox C57BL/6) component mice were either obtained from The Jackson
Laboratory (Kras and p53) or from Dr. Sunil Hingorani (p48, University of
Washington, WA, USA) and have been previously described64. KPC experiments
were performed with mice of mixed genders and mice were analyzed at end stage,
deﬁned as approximately 6 months of age or when tumors reached 1.0 cm, the
animal experienced >15% weight loss, or other absolute survival event. For genetic
models, aged matched littermates lacking oncogene expression were used as tumor-
free controls. Zbtb46-GFP (B6.129S(C)-Zbtb46tm1.1Kmm/J), IRF8−/− (B6(Cg)-
Irf8tm1.2Hm/J) and Batf3−/− (B6.129S(C)-Batf3tm1Kmm/J) mice in the C57BL/6
background were obtained from The Jackson Laboratory and have been previously
described18,29,66. A total of 2.5 × 105 PyMT-B6, PyMT-mCh-OVA, or 4T1-FL-GFP
cell lines were orthotopically implanted in low growth factor matrigel (Cultrex)
into the mammary fat pad 4/5, while 2 × 105 Pan02 cells were orthotopically
implanted in low growth factor matrigel (Cultrex) into the pancreas. All cell lines
were implanted into C57BL/6 mice, except 4T1, which was implanted into BalbC
mice. PDAC mouse models were analyzed at end stage, deﬁned as tumors reaching
1.0 cm, the animal experienced >15% weight loss, or other absolute survival event.
BC mouse models were analyzed at end stage, deﬁned as tumors reaching 1.5 cm,
the animal experienced >15% weight loss, or other absolute survival event. For
secondary tumor experiments, 5 × 105 PyMT-mCh-OVA cells were implanted into
mammary fat pad 2/3 when the 2.5 × 105 PyMT-B6 cells implanted into the
mammary fat pad 4/5 produced a tumor 1.0 cm in diameter, or into mammary fat
pad 2/3 of non-primary tumor-bearing matched controls. Mice were analyzed
1 week after secondary tumor implant. For anti-Ly6G IgG-treated arm, anti-Ly6G
IgGs treatment, as described below, was started 1 day prior to implantation of the
PyMT-mCh-OVA tumor. For poly I:C OVA-TxRd plug experiments, a 200 μl low
growth factor matrigel with 20 μg poly I:C and 40 μg OVA-TxRd Conjugate
(ThermoFisher Scientiﬁc) was implanted into mammary fat pad 2/3 when 2.5 × 105
PyMT-B6 cells implanted into the mammary fat pad 4/5 produced a tumor 1.0 cm
in diameter, or non-primary tumor-bearing matched controls. Mice were analyzed
10 days after the plug was implanted. Mice for implantation and controls were
obtained from either Charles Rivers Laboratories or The Jackson Laboratories. For
anti-Ly6G IgG-treated arm, anti-Ly6G IgGs, as described below, was started 1 day
prior to implantation of the matrigel plug. For Ccl4-containing plug iteration, a
matrigel plug containing 200 μl low growth factor matrigel with 20 μg poly I:C and
100 ng Ccl4 (PeproTech) was implanted and analyzed as described above. Tumor-
bearing mice were randomized into treatment groups, when necessary. During
randomization, animals were sorted by tumor size in ascending order, and then
separated into groups in descending order. Investigator was blinded to treatment
group during sorting. Groups were determined to have no statistical difference in
average starting tumors size post hoc. Unless otherwise stated, animals were female
C57BL/6 mice implanted with tumors at 7–8 weeks of age and analyzed at
9–12 weeks of age.
Flow cytometry analysis. For mouse tissue, single-cell suspensions were obtained
prior to staining. BM was ﬂushed from long bones for most analyses; for mature
cDC staining, the long bone was crushed and digested in DMEM (Lonza) sup-
plemented with 2 mg/ml collagenase A (Roche) for 25 min at 37 °C with agitation.
For tumor tissue analysis, the mouse was subjected to perfusion with heparin-
phosphate-buffered saline (PBS) (Alfa Aesar, Lonza) solution prior to tissue dis-
section. LNs, tumors, and matrigel plugs were minced and digested in DMEM
(Lonza) supplemented with 2 mg/ml collagenase A (Roche) and DNAse (Sigma)
for 25 min at 37 °C with agitation. All digestions were quenched with fetal bovine
serum (Atlanta Biological). Blood was obtained by cardiac puncture and deposited
in heparin-PBS (Alfa Aesar, Lonza) solution. Blood was then incubated in red
blood cell lysis solution (Biolegend) for 10 min. All samples were washed with 1%
bovine serum albumin (BSA) PBS (Sigma, Lonza) staining buffer and ﬁltered with a
40 μM mesh ﬁlter (FisherBrand) prior to staining. Samples were blocked on ice
with rat anti-mouse CD16/32 for 10 min (except when CD16/32-PE was used).
Samples were then resuspended in 100 μl staining buffer with extracellular
ﬂuorophore-conjugated antibodies and incubated on ice for 30 min. Samples were
washed with staining buffer and ﬁxed with ﬁxation buffer (BD) for 30 min. When
intracellular staining was performed, the ﬁxation/permeabilization kit (eBioscience)
was used after extracellular staining according to the manufacturer’s instructions.
For green ﬂuorescent protein (GFP) analysis, ﬁxation was not performed and cells
were analyzed immediately. Human BM and blood were thawed from cyro-
perservation into PBS (Lonza). Live/Dead or viability dyes were applied for 15–30
min at room temperature (BD). Samples were then processed in the same manner
as the mouse samples above. Data were acquired on the Fortessa X20, LSRII, or
Fortessa system (BD). FlowJo v9 (Tree Star) was used for compensation and
analysis. All antibodies and dilutions used are listed in Supplementary Tables 5 and
6. Markers for cell populations are listed in Supplementary Table 7.
Microarray and RT-qPCR analysis. Total RNA was isolated from GMP, MDP,
and CDP (as deﬁned in gating strategies) from the BM of end-stage PyMT-B6
tumor-bearing mice and tumor-free controls. Lineage depletion was performed
using a Mouse Lineage Depletion Kit (Miltenyi Biotech) according to the manu-
facturer’s instructions. Cells were processed and stained as described above and
sorted on the ARIAII system (BD). RNA was isolated using the E.N.Z.A. Total
RNA Kit (OMEGA) according to the manufacturer’s instructions. Microarrays
were performed on MDP and CDP samples by the Genome Technology Access
Center (GTAC) at Washington University and data have been deposited in the
National Center for Biotechnology Information (NCBI) Gene Expression Omnibus
with accession number GSE99467. Differential gene list was generated and cluster
analysis was performed using genes with detected fold changes >1.5, p < 0.05 and
false discovery rate (FDR) q < 0.05. Microarray data were analyzed using DAVID
Bioinformatics Resource to develop a list of Gene Ontology (GO) Terms67,68. RNA
from GMPs, MDPs, and CDPs was also processed into complementary DNA
(cDNA) using qScript cDNA SuperMix (Quantabio). Target genes were assessed
using quantitative real-time PCR Taqman primer probes set for Irf8, Cd209a,
Zbtb46, Bcl11a, Spi1, SpiB, Cebpe, Gﬁ1, Cebpa, Id2, Batf3, H2-Ke6, H2-Dma, H2-
Q8, Tapbp, Tap2, Pml, Csf3r, Tbp, and Gapdh (Applied Biosystems). Primer assay
IDs are listed in Supplementary Table 8. Relative gene expression was determined
on an ABI7900HT quantitative PCR machine (ABI Biosystems) using Taqman
Gene Expression Master Mix (Applied Biosystems). The threshold cycle method
was used to determine fold change gene expression normalized to Gapdh and Tbp.
For in vitro gene expression assays, MPs, MDPs, and CDPs were sorted as
described above. Cells were cultured in Rosewell Park Memorial Institute (RPMI)-
1640 medium (Lonza) supplemented with 10% fetal bovine serum (Atlanta Bio-
logical), β-mercaptoethanol (Gibco), non-essential amino acids (Life Technolo-
gies), and L-glutamine (Life Technologies) in the presence of 100 ng/ml
recombinant Flt3L and/or 100 ng/ml recombinant GCSF (PeproTech) for 24 h.
Gene expression for Irf8 was assessed by quantitative reverse transcriptase poly-
merase chain reaction (RT-qPCR) protocol described above.
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Immunohistochemistry (IHC) and in situ hybridization (ISH). Human PDAC
and breast cancer tissue microarray (TMA) samples were stained using anti-GCSF
IgGs (ab9691, Abcam) diluted 1:25 in blocking buffer (5% goat serum, 2.5% BSA in
1× PBS) on Bond Rxm autostainer. Antigen retrieval was performed using citrate-
based Epitope Retrieval Solution (AR9961, Leica Biosystems), and immunostaining
was visualized using 3,3′-diaminobenzidine by Bond Polymer Reﬁne Detection Kit
(DS9800, Leica Biosystems) using manufacturer’s recommendations. Human
PDAC and breast cancer TMA-stained slides were scanned at 10× magniﬁcation
on Zeiss Axio Scan Z1 Brightﬁeld/Fluorescence Slide Scanner, visualized and
graded based on staining intensity. ISH was performed on mouse tumor and BM
tissues isolated from end-stage PyMT-B6 and KPC mice and age-matched normal
mammary glands, pancreas, and BM. Tissues were ﬁxed in 10% formalin
o/n at 4 °C and embedded in parafﬁn. Then, 6 µM sections were taken, dried
overnight, and stained with ISH probe speciﬁc for CSF3 gene (Cat. No. 400918,
ACD) using the RNAscope 2.5 LS Duplex Assay (Cat. No. 32240, ACD) using the
manufacturer’s recommendations for Leica Bond Rxm. For all quantiﬁcations,
whole tissue slide scans were obtained at 10× or 20× magniﬁcation on Zeiss Axio
Scan Z1 Brightﬁeld/Fluorescence Slide Scanner. Additional 20× brightﬁeld images
were taken on the Nikon Eclipse 80i Epiﬂuorescence microscope (Nikon). Whole
tissue slide scans at 20× magniﬁcation were analyzed with HALO software (Indica
Labs) using the Chromogenic RNA ISH Module. This allowed for thresholding and
detection of positive probe staining on a single-cell basis to quantify average
number of probe copies per cell.
In vitro dendritic cell differentiation. BM cells were isolated, lineage depleted,
and stained as described above. CD45.2+ MPs (Lin-cKit+ScaI−), MDPs, or CDPs
were isolated from whole BM of tumor-bearing or tumor-free mice by cell sorting
on the ARIAII system (BD). A total of 2500 sorted progenitors were plated on
1.125 × 106 CD45.1+ BM cell feeder culture in RPMI-1640 medium (Lonza) sup-
plemented with 10% fetal bovine serum (Atlanta Biological), β-mercaptoethanol
(Gibco), non-essential amino acids (Life Technologies), and L-glutamine (Life
Technologies) in the presence of 100 ng/ml recombinant Flt3L and/or 100 ng/ml
recombinant GCSF (PeproTech) in 24-well plates. The medium was replaced after
3 days and cultures were analyzed after 5 days. To lift cells, 0.05% Trypsin
(HyClone) was used. Cells were stained and analyzed as described for ﬂow cyto-
metry, identifying the progeny of isolated progenitors by CD45.2 positivity. For
GCSF priming experiment, progenitors were treated with 100 ng/ml GCSF or
media alone for 24 h prior to plating in differentiation assay described above.
IRF8 overexpression in vitro. Retroviral vectors, MSCV Irf8 T2a Thy1.1, or
MSCV empty vector T2a Thy1.1 control were obtained from Drs. Theresa and
Kenneth Murphy (Washington University in Saint Louis, St. Louis, MO). Vectors
were transfected into Phoenix-E cells using Trans-IT LT-1 (Mirus) according to the
manufacturer’s instructions. Virus was collected at 48 h after transfection and
concentrated by spin at 25,000 rpms for 2 h. CD45.2+Lin-cKit+ScaI−MPs were
sorted at previously described and infected with concentrated virus in 8 μg/ml
polybrene by spin infection at 1800 rpms for 45 min. Infection was allowed to
proceed overnight. Cells were then plated into dendritic cell differentiation assay
described above. Cells were analyzed at 3 days. Cells were maintained in 100 ng/ml
Flt3L and/or 100 ng/ml GCSF through infection and differentiation assay.
In vivo differentiation. BM CD45.1+Lin−cKit+ScaI−MPs were isolated as
described above and transferred into sub-lethally irradiated 1.0 cm PyMT-B6
tumor-bearing mice and tumor-free controls by retro-orbital injection. After
2 weeks, CD45.1+ populations were analyzed by ﬂow cytometry as described
above.
MDP/CDP adoptive transfer. BM MDP and CDPs were isolated as described
above from the tumor-free mice and mice bearing end-stage orthotopic PyMT-B6
tumors. A total of 26,000 cells were adoptively transferred into each BATF3−/−
mouse by retro-orbital injection. PyMT-mCh-OVA was implanted as described
above 3 days after adoptive transfer.
Cytokine analysis. Blood serum was isolated from end-stage PyMT-B6 tumor-
bearing mice and tumor-free controls. Blood was collected by cardiac puncture and
allowed to clot for 30 min at room temperature. Clotted blood was separated by
spinning at 1000 × g for 15 min. Serum cytokines were measured by Milliplex
Multiplex Assay (EMD Millipore) according to the manufacturer’s instructions.
Assays were analyzed on the Luminex 100 (Luminex Corp.). Serum Flt3L was
measured by Mouse Flt-3 Ligand DuoSet ELISA (R&D Systems) according to the
manufacturer’s instructions. Serum GCSF was measured by Mouse GCSF DuoSet
ELISA (R&D Systems) according to the manufacturer’s instructions. Human
patient serum was analyzed for GCSF using a Human GCSF ELISA Kit (Abcam)
according to the manufacturer’s instructions.
In vivo cytokine, antibody and drug treatment. Mice were subcutaneously
injected with 2 μg recombinant GCSF (PeproTech) in 100 μl PBS every day for
10 days. Mice bearing 1.0 cm diameter PyMT-B6 tumors were treated with 30 μg
Flt3L (Celldex) daily for 9 days by intraperitoneal injection. Mice bearing 1.0 cm
diameter PyMT-B6 tumors were treated with 50 μg anti-GCSF IgGs (clone 67604,
R&D Systems), 500 μg anti-IL-6 IgGs (clone MP5-20F3, BioXCell), or matched
isotype control three times per week by intraperitoneal injection for 2 weeks. Mice
were treated with anti-Ly6G IgGs (clone 1A8, BioXCell) or matched isotype
control, ﬁrst dose 400 μg, 100 μg for subsequent doses, three times per week
beginning at time point indicated in the experiment. Mice were treated with 200 μg
anti-PD1 IgGs (clone RMP1-14, BioXCell) every 3 days by intraperitoneal injec-
tion. Mice were treated with 50 μg poly I:C every 5 days by intratumoral injection,
according to time points indicated in the experiment.
Statistical analysis. GraphPad Prism Version 5 (GraphPad Software Inc.) was
used for statistical analyses. The sample size was determined for all human and
mouse analyses and in vivo experiments using experimental data from other stu-
dies to estimate appropriate numbers of samples and mice to achieve >85% con-
ﬁdence for a twofold change in any given parameter at the p < 0.05 signiﬁcance
level. The number of animals and in vitro replicates is speciﬁed in the ﬁgure
legends. Variance was analyzed using an F-test. Parametric data were compared
using an unpaired t test. Non-parametric data were compared using the
Mann–Whitney U-test. The p < 0.05 was considered statistically signiﬁcant. Data
sets were tested for outliers using Grubbs’ test (extreme studentized deviate
method). For tumor burden studies, two-way analysis of variance (ANOVA) was
used to compare groups and p < 0.05 was considered statistically signiﬁcant.
Spearman’s correlation was used to compare human data points. For spearman’s
correlations, correlation coefﬁcient (r2) and p values are reported in the ﬁgure. Log-
rank (Mantel–Cox) tests were used to assess differences in survival and p values are
indicated in the ﬁgure; *p < 0.05; **p < 0.01; ***p < 0.001; n.s. denotes not sig-
niﬁcant. All data were presented as mean +/− s.e.m. or as box plots.
Data availability. Microarray data displayed in Fig. 3d and Sup. Figure 6b are
deposited in NCBI Gene Expression Omnibus under accession code GSE99467. All
other remaining data are available within the article and Supplementary Files, or
available from the authors upon request.
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